Month: November 2025

The FDA recently approved a new sub-q therapy, Dawnzera (donidalorsen) from Ionis Pharmaceuticals, Inc. indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. Dawnzera is the first and only RNA-targeted medicine approved for HAE, designed to target plasma prekallikrein (PKK), a key protein that activates inflammatory mediators associated with acute attacks of HAE. Dawnzera was designed to target plasma prekallikrein, a protein that activates inflammatory mediators associated with acute attacks of HAE.

Dawnzera represents a first-in-class therapy for hereditary angioedema (HAE), offering a new approach to disease management. This subcutaneous treatment is designed to be self-administered, providing greater convenience for patients. According to Ionis, Dawnzera’s ease of use and self-administration make it a preferred prophylactic option for many individuals living with HAE.

Dawnzera has demonstrated the ability to reduce sudden and often unpredictable flareups that characterize HAE of severe swelling affecting the limbs, the face and other bodily areas. HAE affects 7,000 people in the U.S. and can be fatal resulting from restricted airways.

It is reported that the cost of Dawnzera will be $57,462 per dose or $747,000 annually based on the maximum dosing (q4 week) schedule.

Dawnzera will be available through specialty pharmacy distribution. Orsini Specialty Pharmacy has been selected as the exclusive SP partner for Dawnzera.

CLICK HERE to access prescribing information

---

DAWNZERA (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

CLICK HERE to read the company press release

Manufacturers of rare disease and specialty products in the U.S. face an increasingly intricate distribution landscape. What once looked like a relatively simple path from drug to patient now demands strategic alignment across state and federal compliance, logistics models, and evolving legislation that threatens to upend established networks.

The article we are spotlighting today opens the curtain to see several key emerging challenges for Pharma. A full read of the article will add significant color to this short summary Report.

State Licensure Regimes & Virtual Distribution Risks
Each U.S. state (and D.C.) enforces its own licensing rules for drug distributors, creating significant burdens for national operations. Many states now extend these requirements to “virtual distributors” that transfer title or broker products without physical facilities, meaning even remote or non-handling manufacturers may still need state licensure.

Distribution Models as Compliance Tools
To mitigate state licensing burdens, manufacturers are exploring variants of 3PL and title transfer models each carrying trade-offs in cost, control, regulatory risk, and operational complexity:

• A “flash title” model transfers ownership to a 3PL briefly to satisfy state licensing rules, though the 3PL may not perform storage or distribution.
• A full 3PL title model transfers both title and possession to the logistics provider, allowing the manufacturer to outsource licensure burdens to that party.

State-Level Network Restrictions & Limited Distribution Network Pressures
States are tightening oversight of “limited distribution networks” (LDNs) even prohibiting manufacturers from restricting distribution to out-of-state pharmacies without offering comparable local access or board-approved justification. Specialty drug makers relying on LDNs must monitor such laws and prepare for penalties.

Federal Healthcare Compliance Layers
Beyond state hurdles, any arrangement with 3PLs or distributors must respect Anti-Kickback rules and government price reporting obligations. Manufacturers must properly assess and document fair market value (FMV) for services rendered, especially when using novel title/3PL structures, to avoid kickback or overpayment risks.

For Pharma manufacturers in the rare/specialty segment, each drug’s distribution strategy must now be as carefully governed as its clinical strategy.

---

Rare Disease and Specialty Product Manufacturers: Distribution Model Considerations

CLICK HERE to read the full article

The FDA recently approved Papzimeos (zopapogene imadenovec-drba), a new therapy from Precigen Inc., for the treatment of adults with recurrent respiratory papillomatosis (RRP). This marks the first and only approved therapy available for the rare condition.

RRP is a debilitating and sometimes life-threatening disease caused by chronic infection with HPV types 6 or 11. The infection leads to recurrent benign tumors, or papillomas, within the respiratory tract. While typically noncancerous, papillomas consist of abnormal epithelial cell growths that can obstruct airways and require repeated surgical interventions.

RRP affects an estimated 27,000 adults in the United States, highlighting the unmet need for effective treatment options. Until now, patients have relied primarily on repeated surgical procedures to manage symptoms.

According to Precigen, Papzimeos published a defined dosing schedule: patients receive treatment on day one, followed by another dose at week two, and then once every four weeks thereafter. The therapy is supplied as a frozen suspension for subcutaneous injection. Prescribing information states that the therapy be rapidly thawed and immediately administered. Given the complexity of the disease, need for close monitoring, and preparation & handling, administration will take place in a specialist’s office.

Precigen has announced a list price of $115,000 per vial, totaling approximately $460,000 for the first twelve-week course of treatment.
Distribution and logistics details have not yet been disclosed.

CLICK HERE to access prescribing information

---

Precigen Announces Full FDA Approval of Papzimeos (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

CLICK HERE to access the press release

In the ever-evolving landscape of specialty pharmaceuticals, affordability and access remain front and center for patients, payers, and pharmacies alike. MedImpact Holdings Inc. is now poised to make a significant stride in this arena with the announcement of direct access to an unbranded biosimilar version of ustekinumab-aekn, a lower-cost alternative to the well-known reference drug, Stelara.

Breaking Down the Announcement
MedImpact’s new biosimilar will be distributed by Anda, affiliated with Teva Pharmaceuticals USA, Inc., and available for purchase from Birdi, Inc., MedImpact’s preferred partner. Most importantly, any licensed specialty pharmacy will have access to this product, potentially opening the door to wider market competition.

It is well known that a drug’s cost rises at each step in the supply chain. By adopting an unbranded strategy, MedImpact aims to bypass traditional markups and inefficiencies that inflate prices along the journey from manufacturer to patient. The program will provide specialty pharmacies with a new sourcing channel… not just MedImpact clients… more choice and control over their pharmacy benefit spending.

The model is also about transparency. Moving away from convoluted rebate structures and towards clear, upfront pricing gives payers and members access to true costs when the medication is dispensed.

Will this program start a sea change in the marketplace? MedImpact’s move is more than just another product launch… it’s a signal of changing tides in specialty pharmacy, where value, choice, and transparency are fast becoming the new standard. The availability date for the unbranded ustekinumab-aekn biosimilar is January 01, 2026.

---

MedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US

CLICK HERE to read the full press release

The FDA recently approved a new ORAL therapy, Brinsupri (brensocatib) from Insmed Inc., indicated for the treatment of non-cystic fibrosis bronchiectasis in adult and pediatric patients 12 years of age and older.  Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor and is the first and only treatment for the condition. Non-Cystic Fibrosis Bronchiectasis is a serious, chronic lung disease that can lead to permanent lung damage.

Approximately 500,000 U.S. patients are diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB). This approval offers patients effective treatment to defer the frequent exacerbations when symptoms worsen. Symptoms include coughing, increased mucus, shortness of breath and fatigue. Until now, treatment options were limited to antibiotics, airway clearance devices, and in severe cases, surgery.

Insmed will price Brinsupri at $88,000 per year before discounts during a company conference call.

The company also confirmed that Brinsupri will launch via specialty pharmacy limited distribution. Three SPs have confirmed their selection by Insmed as a distributor of the therapy, PantherRx Rare, Maxor Specialty Pharmacy, and Amber Specialty Pharmacy.

CLICK HERE to access prescribing information

—————————————————————————————-

FDA Approves BRINSUPRI (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

CLICK HERE to read the company press release

We are all aware that orphan disease drugs are typically very expensive. Yet, health plans tend to avoid risk-sharing arrangements that could significantly mitigate those costs. Reluctance stems from diverse factors such as the differences in dosing schedules (daily vs. weekly, etc.), administration routes (provider- vs. patient-administered), and tolerability issues, etc. Collectively, the abundant variables of each unique course of treatment create significant barriers to implementing and tracking risk contract performance.

But, the landscape is changing. Between 2020 and 2024, roughly 20-25 new orphan drugs gained FDA approval annually, with projections indicating 160-200 more could enter review by 2030. Many of these new treatments include gene and cell therapies, biologics, and high-cost small molecules for the same conditions. This increasing pipeline will likely lead to multiple high-priced options competing for the same orphan indication, intensifying market competition.

As more therapies emerge for the same conditions, will pricing pressures curb future growth, especially if new treatments do not demonstrate significant clinical benefits? To justify premium pricing amid stiff competition, later entrants might consider risk-sharing contracts, especially if they can substantiate clinically meaningful advantages.

Can risk contracting be that key differentiator? Risk contracts are particularly appealing when clinical data support superior outcomes, enabling companies to justify higher prices. Such contracting aligns well with the rising emphasis on value-based care in managed health plans and presents a strategic opportunity for new entrants to position themselves as committed to delivering that value.

With an expanding pipeline, building risk-sharing arrangements into drug launch strategies could be a necessity for orphan drug developers… provided they can minimize operational burdens on payers.

---

Risk Contracting When Orphan Disease Space is Crowded

Health plans face challenges in risk arrangements for orphan drugs, but increasing competition may open doors for innovative pricing strategies.

CLICK HERE to read the full article